Evercore ISI lowered the firm’s price target on Cardinal Health (CAH) to $110 from $118 and keeps an In Line rating on the shares. Ahead of distributor earnings starting next week and post this week’s Optum (UNH) contract update, the firm is adjusting its Cardinal and McKesson (MCK) models for the Optum contract change as well as Cardinal’s new segments. For McKesson, the firm has raised its Pharma AOI expectations for FY25 following the Optum win and says it sees this and other factors as likely to provide upside to FY25 guidance compared to current Street expectations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health Announces New Business Structure and Segments
- Cardinal Health weakness a buying opportunity, says Baird
- McKesson won OptumRx contract lost by Cardinal, says Evercore
- Cardinal Health Ends Pharmaceutical Distribution Deal with OptumRx
- Cardinal Health sees FY25 EPS growth, consensus $7.99
